FDA launched its Expedited IND Pilot last week. Why? Well, first-in-human development can take up to two years in the United States, while comparable programs move faster in China and Australia.
In short, the FDA is responding to competition by testing whether rolling review and partnerships with qualified research institutions can identify deficiencies earlier, reduce clinical holds, and move studies into humans faster. The agency plans to select eight to ten sponsor-qualified research institution (QRI) pairs, while retaining full authority over whether each trial may proceed.
The FDA has a vantage point on this that no sponsor, CRO, or industry commentator can match. It sees where INDs stall, why clinical holds occur, and which parts of early development consume time without adding equivalent value. So when the agency decides the current model warrants an experiment, I pay attention. Competition may have supplied the urgency, but presumably the FDA’s own experience supplied the evidence.
What the pilot actually changes
The mechanism is rolling review. Under the standard path, a sponsor assembles a complete IND package — nonclinical pharmacology and toxicology, chemistry and manufacturing, the clinical protocol — and submits it as one package, after which FDA has thirty days to respond. Problems in any one section surface only at the end, and a clinical hold sends the whole package back.
In the pilot, FDA will accept and review individual components as they are finished rather than waiting for the complete submission. A CMC gap gets flagged while the tox package is still being written, instead of after. The agency is also testing whether the pairing can compress what happens after the study is allowed to proceed — IRB review and site activation, which routinely consume weeks that nobody counts as regulatory time.
The second mechanism is the pairing itself. Each sponsor works with a Qualified Research Institution that advises across the disciplines an IND touches. The theory is that a stronger submission arrives in the first place.
Who can apply, and who cannot
The eligibility criteria are narrower than most of the coverage has suggested. A sponsor needs a novel product candidate under the jurisdiction of CDER's Office of New Drugs, CBER's Office of Therapeutic Products, or the Oncology Center of Excellence; a commercial IND, meaning genuine intent to commercialize; a Phase 1 first-in-human submission for a product with no established clinical experience; enough preliminary nonclinical data at the time of application; and a Phase 1 trial planned for the United States.
The exclusions matter just as much. The pilot does not prioritize new formulations, delivery systems or technologies, drug-device combinations, new routes of administration or dosage forms, or anything developed under the 505(b)(2) pathway. If your program is a reformulation or a device pairing, this is not your program.
Participation is voluntary and confers no advantage on the science. FDA has been explicit that not being selected does not disadvantage a sponsor, does not affect access to pre-IND meetings, and implies nothing about the quality of the development program.
What a Qualified Research Institution has to be
QRI is a new label, and it is broader than "academic medical center." FDA's criteria admit health networks, contract research organizations, regulatory advisors and other research organizations. What the label requires is demonstrated expertise across nonclinical pharmacology and toxicology, chemistry, manufacturing and controls, clinical trial design under board-certified physician leadership, clinical pharmacology where applicable, regulatory affairs coordination, and either Phase 1 trial infrastructure or a documented partnership that supplies it.
There is also a structural requirement worth noting: the QRI must be a legal entity organized in the United States, with its principal place of business here and its core advisory personnel located here. And both parties need written conflict-of-interest procedures. Where a QRI has an affiliated IRB, that IRB's members cannot hold dual roles in the QRI's advisory process during the pilot.
That last requirement is the one I would read twice. A CRO can be a QRI. If your CRO advises on your IND and then runs the study, the independence question is not theoretical, and the conflict-of-interest documentation will not answer it by itself.
The dates
Applications opened 15 September 2026 and close 30 October 2026. FDA expects to announce the selected cohort on 18 December 2026, and has said timelines may shift depending on volume. Eight to ten pairs will be chosen.
Five weeks is not long to identify a QRI, agree on an engagement model, document conflict-of-interest procedures, and assemble an application describing your program's stage and your proposed rolling submission sequence. If you are considering it, the QRI conversation is the one to start this week.
What this means if you are choosing a CRO right now
For the overwhelming majority of sponsors — everyone outside eight to ten pairs — the pilot changes nothing operationally this year. It is worth watching rather than planning around.
What it does confirm is something sponsors have known without institutional backing: the delays in early development are rarely scientific. They are handoffs, sequencing, and submissions that arrive incomplete because nobody owned the whole package. That is an operating-model problem, and it does not require a federal pilot to fix. A sponsor that sequences its own nonclinical, CMC and clinical workstreams deliberately, and holds its vendors to a schedule that reflects that sequence, captures most of what rolling review is trying to buy.
If you do apply, one thing to settle before you sign anything: which decisions belong to you and which belong to the QRI. A pilot designed to reduce handoffs will not help a sponsor who adds one.
I support the pilot, but the burden of proof sits squarely with the QRI model. Will qualified research institutions improve the path to first participant dosed or simply move the delays upstream, adding cost, handoffs, and another layer of coordination? If they make submissions stronger and timelines more predictable without placing smaller biotechs at a disadvantage, the model will have made a persuasive case for itself. If not, we will have made the machinery more elaborate without making it move any faster.
Whether or not the pilot changes the timeline, the sponsor still owns the decisions that set it. ABRA works on choosing and governing a CRO for a first-in-human study.
